贺军侨 1易平勇 1刘晰宇 1周芳 1欧阳周 1孙中义 1黄利军 1姚远1
作者信息
- 1. 湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院 淋巴瘤血液内科，湖南 长沙，41006
- 折叠
摘要
Abstract
Objective We evaluated the efficacy of R-CHOP and CHOP in first-line treatment of early primary gastric dif-fuse large B-cell lymphoma. Methods Sixteen patients with early (stage I-II) gastric diffuse large B-cell lymphoma received R-CHOP immunochemotherapy as first-line treatment. The R-CHOP regimen consisted of rituximab (375 mg·m-2 intra-venously) on day 1, cyclophosphamide (750 mg·m-2 intravenously) on day 2, doxorubicin (50 mg·m-2 intravenously) on day 2, vincristine (1.4 mg·m-2 intravenously) on day 2 and prednisone (100 mg orally) on days 2 ~ 6. Another group of 16 patients with early (stage I ~ II) gastric diffuse large B-cell lymphoma received CHOP chemotherapy as first-line treatment. A non-randomized comparison of efficacy was conducted between R-CHOP and CHOP group. The CHOP regimen consisted of cy-clophosphamide (750 mg·m-2 intravenously) on day 1, doxorubicin (50 mg·m-2 intravenously) on day 1, vincristine (1.4 mg·m-2 intravenously) on day 1 and prednisone (100 mg orally) on days 1 ~ 5. The efficacy and adverse events of both regimens were evaluated and compared. Results All the 32 patients were evaluated. In the R-CHOP group, the treatment consisted of 2 ~ 6 cycles (median, 4 cycles) of immunochemotherapy, and eight patients achieved complete remission (CR), six patients partial re-mission (PR), one patient stable disease (SD), one patient progression disease (PD). The responsive rate of R-CHOP was 87.5% (14/16). In the CHOP group, the treatment consisted of 2-6 cycles (median, 4 cycles) of chemotherapy, and six patients achieved CR, five PR, two patients SD, three patients PD. The responsive rate of CHOP was 68.7% (11/16). The response rate was higher in the R-CHOP group than in the CHOP group, and the difference was statistically significant. The adverse events in both two groups consisted of myelosuppression, infection, mucositis, gastrointestinal reactions, fever, liver and kidney dysfunction, neuro-toxicity and allergic reactions. All the adverse events can be rapidly eased after symptomatic treatment. Except for fever, there was no significant difference in the incidence of adverse events between R-CHOP group and CHOP group. Conclusion R-CHOP was more effective than CHOP regimen as first-line treatment of early gastric diffuse large B-cell lymphoma, and there was no significant difference in the incidence of toxicities between the two regimens.关键词
弥漫大B细胞淋巴瘤/胃/利妥昔单抗/药物治疗Key words
Diffuse large B-cell lymphoma/Stomach/Rituximab/Medication分类
医药卫生
